{"id":"NCT00772447","sponsor":"AstraZeneca","briefTitle":"China Registration Study in Patients With Skin Infections","officialTitle":"A Phase 3, Multicentre, Randomised, Investigator-blinded, Parallel-groupStudy of the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects With cSSSI","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-10-15","resultsPosted":"2015-03-09","lastUpdate":"2015-03-09"},"enrollment":265,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Skin Diseases","Infectious"],"interventions":[{"type":"DRUG","name":"Daptomycin","otherNames":["Cubicin®"]},{"type":"DRUG","name":"Vancomycin","otherNames":[]}],"arms":[{"label":"AZ drug","type":"EXPERIMENTAL"},{"label":"Comparator","type":"ACTIVE_COMPARATOR"}],"summary":"The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.","primaryOutcome":{"measure":"Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)","timeFrame":"baseline to TOC(test of cure), for up to 4 weeks","effectByArm":[{"arm":"Daptomycin","deltaMin":0,"sd":0.08},{"arm":"Vancomycin, or Vancomycin Switch to Cloxacillin","deltaMin":0.01,"sd":0.033}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":13,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=300&filename=CSR-D1790C00003.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=300&filename=CSR-D1790C00003.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["ALANINE AMINOTRANSFERASE INCREASED","Aspartate Aminotransferase Increased","UPPER RESPIRATORY TRACT INFECTION","Blood Creatine Phosphokinase Increased","WHITE BLOOD CELL COUNT DECREASED"]}}